95 related articles for article (PubMed ID: 29146051)
1. Beta-catenin and p53 expression in topographic compartments of colorectal cancer and its prognostic value following surgery.
Prieto JD; Álvarez M; Hierro MI; García I; Vicioso L
Ann Diagn Pathol; 2017 Dec; 31():1-8. PubMed ID: 29146051
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of beta-catenin and p53 expression in the metastatic progression of sporadic colorectal cancer.
Pancione M; Forte N; Fucci A; Sabatino L; Febbraro A; Di Blasi A; Daniele B; Parente D; Colantuoni V
Hum Pathol; 2010 Jun; 41(6):867-76. PubMed ID: 20129645
[TBL] [Abstract][Full Text] [Related]
3. Relationship between osteopontin and β-catenin immunohistochemical expression and prognostic parameters of colorectal carcinoma.
Youssef NS; Osman WM
Int J Clin Exp Pathol; 2015; 8(2):1503-14. PubMed ID: 25973035
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of survivin, β-catenin and p53 expression in urothelial carcinoma.
Senol S; Yildirim A; Ceyran B; Uruc F; Zemheri E; Ozkanli S; Akalin I; Ulus I; Caskurlu T; Aydin A
Bosn J Basic Med Sci; 2015 Aug; 15(4):7-14. PubMed ID: 26614845
[TBL] [Abstract][Full Text] [Related]
5. Beta-catenin expression in relation to genetic instability and prognosis in colorectal cancer.
Mårtensson A; Oberg A; Jung A; Cederquist K; Stenling R; Palmqvist R
Oncol Rep; 2007 Feb; 17(2):447-52. PubMed ID: 17203186
[TBL] [Abstract][Full Text] [Related]
6. [Expressions of beta-catenin, p53 and proliferating cell nuclear antigen in the carcinogenesis of colorectal adenoma].
Wu W; Zhang X; Yan X; Wang J; Zhang J; Li Y
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):264-7. PubMed ID: 12515622
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of BMP and activin membrane-bound inhibitor in colorectal cancer.
Togo N; Ohwada S; Sakurai S; Toya H; Sakamoto I; Yamada T; Nakano T; Muroya K; Takeyoshi I; Nakajima T; Sekiya T; Yamazumi Y; Nakamura T; Akiyama T
World J Gastroenterol; 2008 Aug; 14(31):4880-8. PubMed ID: 18756595
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Wnt and β-catenin Expression in Advanced Colorectal Cancer.
Yoshida N; Kinugasa T; Ohshima K; Yuge K; Ohchi T; Fujino S; Shiraiwa S; Katagiri M; Akagi Y
Anticancer Res; 2015 Aug; 35(8):4403-10. PubMed ID: 26168479
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis.
Lugli A; Zlobec I; Minoo P; Baker K; Tornillo L; Terracciano L; Jass JR
Histopathology; 2007 Mar; 50(4):453-64. PubMed ID: 17448021
[TBL] [Abstract][Full Text] [Related]
10. Correlations between clinicopathological parameters and molecular signatures of primary tumors for patients with stage T3n0 colorectal adenocarcinomas: a single center retrospective study on 100 cases.
András C; Tóth L; Molnár C; Tanyi M; Csiki Z; Dezso B; Pósán J; Shemirani AH; Csiki E; Szántó J
Hepatogastroenterology; 2012 Jun; 59(116):1091-7. PubMed ID: 22414548
[TBL] [Abstract][Full Text] [Related]
11. B-cell lymphoma 2 and β-catenin expression in colorectal cancer and their prognostic role following surgery.
Balzi M; Ringressi MN; Faraoni P; Booth C; Taddei A; Boni L; Bechi P
Mol Med Rep; 2015 Jul; 12(1):553-60. PubMed ID: 25738398
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness.
Tsujikawa H; Masugi Y; Yamazaki K; Itano O; Kitagawa Y; Sakamoto M
Hum Pathol; 2016 Apr; 50():24-33. PubMed ID: 26997435
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the correlation of KAI1/CD82, CD44, MMP7 and β-catenin in the prediction of prognosis and metastasis in colorectal carcinoma.
Wu Q; Yang Y; Wu S; Li W; Zhang N; Dong X; Ou Y
Diagn Pathol; 2015 Sep; 10():176. PubMed ID: 26408312
[TBL] [Abstract][Full Text] [Related]
14. β-catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients.
Schirosi L; Mazzotta A; Opinto G; Pinto R; Graziano G; Tommasi S; Fucci L; Simone G; Mangia A
Oncotarget; 2016 Oct; 7(42):67841-67850. PubMed ID: 27765918
[TBL] [Abstract][Full Text] [Related]
15. The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC.
Voorneveld PW; Kodach LL; Jacobs RJ; van Noesel CJ; Peppelenbosch MP; Korkmaz KS; Molendijk I; Dekker E; Morreau H; van Pelt GW; Tollenaar RA; Mesker W; Hawinkels LJ; Paauwe M; Verspaget HW; Geraets DT; Hommes DW; Offerhaus GJ; van den Brink GR; Ten Dijke P; Hardwick JC
Br J Cancer; 2015 Jan; 112(1):122-30. PubMed ID: 25393365
[TBL] [Abstract][Full Text] [Related]
16. p53 and beta-catenin expression in gallbladder tissues and correlation with tumor progression in gallbladder cancer.
Ghosh M; Sakhuja P; Singh S; Agarwal AK
Saudi J Gastroenterol; 2013; 19(1):34-9. PubMed ID: 23319036
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical and mutational analyses of beta-catenin, Ki-ras, and p53 in two subtypes of colorectal mucinous carcinoma.
Ikeda S; Shimizu Y; Fujimori M; Ishizaki Y; Kurihara T; Ojima Y; Okajima M; Asahara T
Clin Cancer Res; 2003 Nov; 9(15):5660-5. PubMed ID: 14654549
[TBL] [Abstract][Full Text] [Related]
18. Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability.
Brändstedt J; Wangefjord S; Nodin B; Eberhard J; Jirström K; Manjer J
BMC Cancer; 2014 May; 14():371. PubMed ID: 24885829
[TBL] [Abstract][Full Text] [Related]
19. Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosis.
Gebert C; Hardes J; Kersting C; August C; Supper H; Winkelmann W; Buerger H; Gosheger G
Histopathology; 2007 Mar; 50(4):491-7. PubMed ID: 17448025
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of WNT pathway in surgically-treated colorectal cancer: β-catenin expression predicts for disease-free survival.
Kamposioras K; Konstantara A; Kotoula V; Lakis S; Kouvatseas G; Akriviadis E; Vrettou E; Dionysopoulos D; Krikelis D; Papadopoulou K; Charalambous E; Chrisafi S; Konstantaras C; Fountzilas G
Anticancer Res; 2013 Oct; 33(10):4573-84. PubMed ID: 24123033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
